Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Friday. They presently have a $2.00 price target on the stock, down from their previous price target of $6.00. HC Wainwright’s target price indicates a potential upside of 1.01% from the stock’s current price.
A number of other equities research analysts have also recently weighed in on the company. Citigroup Inc. cut their price target on Mirna Therapeutics from $4.50 to $2.00 and set a “neutral” rating on the stock in a report on Thursday, September 22nd. Leerink Swann reaffirmed a “neutral” rating and set a $1.50 price target (down previously from $4.00) on shares of Mirna Therapeutics in a report on Wednesday, September 21st. Oppenheimer Holdings Inc. cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 21st. Cantor Fitzgerald cut Mirna Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $14.00 to $2.00 in a report on Wednesday, September 21st. Finally, Zacks Investment Research raised Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Wednesday, September 7th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $3.88.
Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.98 on Friday. The firm’s 50-day moving average price is $2.92 and its 200 day moving average price is $4.05. The stock’s market capitalization is $41.25 million. Mirna Therapeutics has a 1-year low of $1.82 and a 1-year high of $11.01.
Mirna Therapeutics Company Profile
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.